Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.53 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.53 |
| ▸ | HTR3B | O95264 | 4/20 | 0.53 |
| ▸ | HTR3A | P46098 | 4/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201071 | 1.00 | ALDH1A1 (0.62) | ALDH1A1POLBCHRNA7SMN1; SMN2HPGD | |
| SCHEMBL7061976 | 0.90 | ALDH1A1 (0.66) | ALDH1A1POLBCHRNA7HTR3EHTR3B | |
| SCHEMBL7064041 | 0.90 | ALDH1A1 (0.54) | ALDH1A1POLBCHRNA7SMN1; SMN2HPGD | |
| SCHEMBL7219559 | 0.89 | ALDH1A1 (0.51) | ALDH1A1POLBCHRNA7SMN1; SMN2HPGD | |
| SCHEMBL7063801 | 0.88 | ALDH1A1 (0.63) | ALDH1A1POLBCHRNA7HTR3EHTR3B | |
| SCHEMBL4191149 | 0.87 | ALDH1A1 (0.62) | ALDH1A1POLBCHRNA7HTR3EHTR3B | |
| SCHEMBL4193845 | 0.87 | ALDH1A1 (0.62) | ALDH1A1POLBCHRNA7HTR3EHTR3B | |
| SCHEMBL7063186 | 0.87 | ALDH1A1 (0.62) | ALDH1A1POLBCHRNA7HPGDKMT2A | |
| SCHEMBL4201694 | 0.87 | ALDH1A1 (0.62) | ALDH1A1POLBCHRNA7HTR3EHTR3B | |
| SCHEMBL4191154 | 0.87 | ALDH1A1 (0.62) | ALDH1A1POLBCHRNA7HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545537-B9 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | claimed |
| EP-1545537-B1 | ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND STATINS IN COMBINATION | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | EP | claimed |
| US-7001914-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | claimed |
| US-20050256146-A1 | Alpha-7 nicotinic receptor agonists and stains in combination | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | claimed |
| EP-1259508-B1 | NOVEL BIARYLCARBOXAMIDES | ASTRAZENECA AB (SE) | 2003-10-15 | — | — | EP | claimed |
| US-6599916-B2 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic acetylcholine receptor is implicated, Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia. | PHARMACIA & UPJOHN COMPANY | 2003-07-29 | — | — | US | claimed |
| EP-1311505-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE ( NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ) | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-21 | — | — | EP | claimed |
| US-20030008867-A1 | Compounds | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | US | claimed |
| US-6500840-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-31 | — | — | US | claimed |
| US-6492385-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-10 | — | — | US | claimed |
| EP-1259508-A1 | NOVEL BIARYLCARBOXAMIDES | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | claimed |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY GLOBAL INTELLECTUAL PROPERTY | 2002-07-11 | — | — | US | claimed |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | claimed |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | claimed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016355-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC) ACETYLCHOLINE RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002017358-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2001060821-A1 | NOVEL BIARYLCARBOXAMIDES | ASTRAZENECA AB (SE) | 2001-08-23 | — | — | WO | claimed |
| US-20090192180-A1 | Alpha-7 Nicotinic Receptor Agonists and Statins In Combination | KEITH RICHARD | 2009-07-30 | — | — | US | disclosed |
| WO-2001060821-A1 | NOVEL BIARYLCARBOXAMIDES | ASTRAZENECA AB (SE) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008867-A1 | Compounds | DRD2, DRD1, GRIN2A | ALDH1A1 75/4885POLB 3437/4885CHRNA7 209/4885 |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | ALDH1A1 130/4885POLB 637/4885CHRNA7 304/4885 |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | ALDH1A1 267/4885POLB 344/4885CHRNA7 28/4885 |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | ALDH1A1 130/4885POLB 637/4885CHRNA7 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.